LGI1-Antibody Encephalitis clinical trials at UCSF
1 research study open to eligible people
LGI1-antibody encephalitis is a brain condition caused by antibodies attacking nerve cells. UCSF is testing how safe and effective the medicine satralizumab is for patients with this condition. Researchers will study the drug's effects on the body in this trial.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for LGI1-Antibody Encephalitis research studies include Jeffrey Gelfand.
Last updated: